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and C-terminal FGF23 levels in non-dialysis chronic
kidney disease patients: post-hoc analysis of a
prospective study
Merche Prats1,3*, Ramon Font1, Carmen García1, Carmen Cabré1, Manel Jariod2 and Alberto Martinez Vea1Abstract
Background: Some parenteral iron therapies have been found to be associated with hypophosphatemia. The
mechanism of the decrease in serum phosphate is unknown. The aim of this study is to examine the effect of IV ferric
carboxymaltose(FCM) on phosphate metabolism and FGF23 levels in patients with chronic kidney disease(CKD).
Methods: This is a post-hoc analysis of a prospective study carried out in 47 non-dialysis CKD patients with
iron-deficiency anaemia who received a single 1000 mg injection of FCM. Markers of mineral metabolism
(calcium, phosphate, 1,25-dihydroxyvitamin D, PTH and FGF23[c-terminal]) were measured prior to FCM
administration and at week 3 and week 12 after FCM administration. Based on the measured levels of serum
phosphate at week 3, patiens were classified as hypophosphatemic or non-hypophosphatemic.
Results: Serum phosphate levels decreased significantly three weeks after FCM administration and remained at lower
levels at week 12 (4.24 ± 0.84 vs 3.69 ± 1.10 vs 3.83 ± 0.68 mg/dL, respectively, p < 0.0001. Serum calcium, PTH and
1,25-dihydroxyvitamin D did not change over the course of the study. Serum FGF23 decreased significantly from
442(44.9-4079.2) at baseline to 340(68.5-2603.3) at week 3 and 191.6(51.3-2465.9) RU/mL at week 12, p < 0.0001. Twelve
patients were non-hypophosphatemic and 35 hypophosphatemic. FGF23 levels decreased in both groups, whereas no
changes were documented in any of the other mineral parameters.
Conclusions: In non-dialysis CKD patients, FCM induces reduction in serum phosphate levels that persists for three
months. FCM causes a significant decrease in FGF23 levels without changes to other bone metabolism parameters.
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deficiency anaemiaBackground
Iron deficiency is common in non-dialysis chronic
kidney disease (CKD) patients and is most pronounced in
haemodialysis patients [1,2]. Supplementation with oral or
intravenous (IV) iron is a common practice in this popula-
tion. Oral iron therapy is limited by poor gastrointestinal
absorption, frequent adverse events and low adherence to
treatment. Therefore, IV iron is the preferred method of* Correspondence: pfk21@hotmail.com
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reproduction in any medium, provided the oriron replacement in these patients [3]. Nevertheless,
high iron doses can lead to serious adverse consequences
such as exacerbation of oxidative stress, inflammation,
endothelial dysfunction, immune deficiency and increased
tissue iron stores [4,5]. There are also other concerns about
currently available IV iron agents, including the potential
for immunogenic reaction, dose limitations and the require-
ment of a test dose, and the desired rate of repletion [6-8].
To overcome these limitations, new IV iron preparations
have been introduced, offering higher single-dose options
with an acceptable side-effect profile [7].
Ferric carboxymaltose (FCM) is an innovative non-
dextran iron complex that is composed of a ferric hydroxided. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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allowing controlled delivery of iron to the target tissues [9].
Unlike earlier forms of IV iron, FCM can be given in a dose
providing up to 1000 mg of iron administered as a rapid
infusion over 15 min. without the need for a test dose [9].
In predialysis CKD patients and in patients undergoing
haemodialysis, FCM is effective and well tolerated, and is
associated with few adverse events [8,10,11]. A common
adverse event associated withg FCM is a transient,
asymptomatic hypophosphatemia, which has been primarily
reported in patients with postpartum iron-deficiency
anaemia and in patients with iron-deficiency anaemia due
to heavy uterine bleeding who were treated with large doses
of FCM [12,13]. However, hypophosphatemia is neither
widely acknowledged nor documented in CKD patients. In
fact, transient hypophosphatemia has only been reported in
2.7% of non-dialysis CKD patients [9] and in 4.3% of a CKD
population [14] treated with FCM, but was not mentioned
in the study conducted by Covic A et al. [8] on anaemic
haemodialysis patients or in the study by Grimmelt A et al.
[10] on predialysis CKD patients treated with variable doses
of FCM.
The cause of hypophosphatemia during IV iron therapy
remains unclear. It has been observed after the administra-
tion of other IV iron preparations such as iron saccharide
[15] or iron polymaltose [16], but not with low molecular
weight iron dextran [7], ferric gluconate [17] or iron
isomaltoside [18]. Because hypophosphatemia has been
reported in association with stimulated erythropoiesis in
other haematopoietic disorders [19-21], it has been sug-
gested that iron-induced hypophosphatemia might be the
result of an increased cellular uptake of phosphate during
erythropoiesis [13]. However, the main mechanism of iron-
induced hypophosphatemia seems to be renal phosphate
wasting [22]. Impaired tubular phosphate reabsorption
has been reported during treatment with saccharated
ferric oxide [15] and with iron polymaltose [16]. In
addition to renal phosphate loss, an inhibition of
renal 25 (OH) D 1α-hydroxylase activity and decreased
1,25-dihydroxyvitamin D levels were also reported in these
cases [15,16].
Since parenteral iron may have a direct toxic effect
on proximal renal tubular cells, renal phosphate loss
could be the consequence of proximal tubular dys-
function induced by iron therapy [23]. Nevertheless,
the dual inhibition of tubular phosphate reabsorption
and 1α-hydroxylation of vitamin D observed during
iron therapy, suggests that a phosphatonin hormone,
fibroblast growth factor 23 (FGF23), may play a role
in the hypophosphatemia induced by IV iron. In fact,
hypophosphatemia with impaired tubular reabsorp-
tion, low 1,25(OH)2 vitamin D and high FGF23 levels
has been reported in anaemic patients with normal
renal function treated with saccharated ferric oxide oriron polymaltose [15,16], supporting an etiologic role
of FGF23 in the development of hypophosphatemia.
In haemodialysis patients, IV low molecular weight
iron dextran [24] or saccharate ferric oxide [25] also
induce an increase in FGF23 levels and a decrease in
PTH levels but no changes in serum phosphate.
To investigate the possible link between FCM ther-
apy and phosphate metabolism, and to ascertain the pos-
sible mechanisms of FCM-associated hypophosphatemia,
a post-hoc analysis was conducted on existing data
from our previous study evaluating FCM therapy in a




This study was performed as a post-hoc analysis of a pro-
spective study carried out in non-dialysis CKD patients
treated with FCM [26]. Subjects ≥ 18 years of age with an
estimated glomerular filtration rate < 60 ml/min/1.73 m2,
serum haemoglobin < 11 g/dL and either serum ferritin <
100 ng/dL or transferrin saturation < 20%, were included
in the study. Exclusion criteria included oral or IV iron
treatment or blood transfusion during the three-month
period prior to the study, active infection, active bleeding,
anticipated dialysis in the next three months, and known
hypersensitivity to other IV iron preparations.
The study was approved by the ethics committee of
the Joan XXIII University Hospital of Tarragona, and all
participants provided written informed consent.
Study design
All patients received a single IV infusion of FCM
(FerinjectR, Vifor Pharma, Switzerlan) over 30 min. at a
maximum dose of 1000 mg(15 mg/Kg) dilute in 250 mL
normal saline, and were monitored for 12 weeks. During
the study period, dietary phosphate intake and doses
of erythropoiesis stimulating agents, active vitamin D,
phosphate binders and cinacalcet hydrochloride were
kept unchanged.
According to levels of serum phosphate obtained at week
three, patients were classified as either hypophosphatemic
or non-hypophosphatemic if phosphate levels decreased
or remained unchanged or even increased compared
to baseline levels.
Biochemical determinations
Blood samples were taken at baseline and at the end
of week 3 and week 12 of the follow-up period.
Serum haemoglobin, transferrin saturation, ferritin,
calcium, phosphate and creatinine were determined
by means of standard laboratory methods. Serum
parathyroid hormone was determined by means of
chemiluminescence(DPC Laboratories, Miami, FL, USA).







Interstitial nephropathy/polycystic kidney disease 3(6%)
Diabetes 12(26%)
Unknown 7(15%)




Use of erythropoiesis stimulating agents 23(49%)
Use of phosphate binders 4(8.5%)
Use of active vitamin D 18(38%)
Use of cinacalcet hydrochloride 1(2%)
Serum creatine, mg/dL 2.56(0.95)
eGFR, ml/min per 1.73 m2 26.1(10.4)
Haemoglobin, g/dL 10(0.7)
Ferritin, ng/mL 67.8(61.7)




25-hydroxyvitamin D, ng/ml 12.8(6.6)
1,25 dihydroxyvitamin D, pg/mL 9.7(4.4)
Fibroblast growth factor 23, RU/mL 442(44.9-4079.2)
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chemiluminiscence(Diasorin, Italy). Serum 1,25 (OH)2 D
levels were measured by RIA(Diasource Immuno Assays,
Belgium). Serum FGF23 concentrations were measured
with the human FGF23 (C-terminal) ELISA kit (Immutopic,
Inc, San Clemente, CA, USA). This C-terminal assay use
two antibodies directed against the carboxyl-terminal
portion of the molecule and detects both total intact
and C-terminal FGF23 [27]. The estimated glomerular
filtration rate(GFR) was calculated using the abbreviated
MDRD formula [28].
Statistical analysis
Statistical analysis was performed using the SPSS/PC,
v.15 statistical package (IMC, Chicago, IL). Values are
expressed as mean ± SD, and in case of PTH and FGF23
levels as median(range). Because serum FGF23 levels
were not normally distributed, log-transformed values
were used in the analysis. Mean levels were compared
between time points using the repeated measurements
ANOVA. The univariate relationship between variables
was assessed by means of Spearman correlations. A p value
of < 0.05 was considered statistically significant.
Results
Study population
A total of 50 patients were enrolled in the study.
Two subjects were withdrawn during the study because
of bleeding, and one patient was excluded due to non-
adherence to study protocol. Thus, 47 patients were in-
cluded in the final analysis. The baseline demographics
and clinical characteristics are shown in Table 1. Mean
age was 72 years, and the most common primary
renal disease was vascular nephropathy. Mean serum
creatinine and estimated GFR were 2.5(0.9) mg/dL
and 26.1(0.4) ml/min/1.73 m2, respectively. Most patients
(85%) were in CKD stages 3–4. Only four patients were
treated with phosphate binders, whereas 18 patients
were receiving active vitamin D: paricalcitol(16 patients),
calcitriol(2 patients). The mean cumulative dose of FCM
was 971.7(69.3) mg. and there were no adverse events
associated with FCM infusion during the study period.
Effect of FCM on iron-deficiency anaemia
Changes in iron indices and haemoglobin concentration be-
fore and after FCM are presented in Table 2. Haemoglobin
levels and serum ferritin and transferrin saturation rose
significantly and remained elevated at the end of the study.
Effect of FCM on mineral parameters
The biochemical parameters of mineral metabolism at base-
line and after FCM infusion are shown in Table 2. Serum
phosphate levels decreased significantly three 3 weeks after
the FCM administration, and remained at lower levels atweek 12. Serum calcium, PTH and 1,25-vit D levels did not
change during the study. However, serum FGF23 decreased
significantly from 442(44.9-4079.2) RU/mL at baseline to
191.6(51.3-2465.9) RU/mL at the end of the study. Changes
in serum phosphate and C-terminal FGF23 were similar in
all stages of CKD. There were no significant changes
in estimated GFR during the study.
The relationship between serum phosphate levels and
mineral metabolis parameters are shown in Table 3.
A significant association was found between serum
phosphate and FGF23 levels at week three. Serum
phosphate was negatively correlated with estimated
GFR throughout the study. There was no correlation
between the decline in phosphate and FGF23 levels at
week 3 or at week 12.
Baseline serum FGF23 levels significantly correlated
with phosphate(r = 0.28, p = 0.05), transferrin saturation
(r = −0.40, p = 0.001), ferritin(r = −0.30, p = 0.007) and
Table 2 Effect of FCM on haemoglobin concentration, iron indices and mineral metabolism parameters
Baseline Week 3 Week 12 p-value
Haemoglobin, g/dL 10(0.7) 10.8(0.8) 11.4(1.3) <0.0001
TSAT, % 14.6(6.4) 28.9(10) 25.6(12.7) <0.0001
Ferritin, ng/mL 67.8(61.7) 502.5(263.3) 230(144.6) <0.0001
Calcium, mg/dl 9.3(0.4) 9.3(0.5) 9.3(0.5) ns
Phosphate, mg/dL 4.2(0.8) 3.6(1.1) 3.8(0.6) <0.0001
PTH, pg/ml 138.1(2.5-600) 124(2.5-736) 106.5(2.5-613) ns
1,25(OH)2 D, pg/mL 9.7(4.4) 10(3.7) 10.4(5.4) ns
FGF23, RU/mL 442(44.9-4079.2) 340(68.5-2603.3) 191.6(51.3-2465.9) <0.0001
TAST: transferrin saturation.
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FGF23 and calcium, 1,25-vit D or PTH was found.
Hypophosphatemic vs non-hypophosphatemic patients
Twelve patiens were non-hypophosphatemic and 35
hypophosphatemic. Age, use of active vitamin D or phos-
phate binders, dose of infused FCM, baseline estimated
GFR, haemoglobin concentration, iron index, and serum
calcium, phosphate, PTH, 25-hydroxy vitamin D and
1.25 vit D levels were similar in both groups (Table 4).
Nevertheless, there was a trend toward higher base-
line FGF23 levels in non-hypophosphatemic than inTable 3 Relationship between phosphate levels and other
mineral metabolism parameters and estimated GFR
Baseline Week 3 Week 12
Phosphate Phosphate Phosphate

















1,25(OH)2 D −0.16 ns
eGFR −0.39 0.007hypophosphatemic patients, but it did not reach statistical
significance. No correlation was demonstrated between
the percentage reduction of serum FGF23 and that of
serum phosphate at any time in either of these groups.
Effect of vitamin D therapy on mineral metabolism
parameters during FCM treatment
Eighteen patients were receiving vitamin D therapy at the
time of the study and 29 were not. Baseline mineral
metabolism parameters and changes in calcium, phosphate,
PTH and 1,25- vit D throughout the study did not differ
between untreated and treated patients. However, the
observed decrease in FGF23 levels in the group of patients
treated with vitamin D was lower than that observed in the
untreated patients: -6.8% (−84.7% to 325.6%) and −36.1%
(−91.6% to 52.4%) at week 3, respectively, and −21.7%
(−66.5% to 46%) and −55.7% (−92.3% to 90.3%) at
week 12, respectively, p = 0.03.
Discussion
In this post-hoc analysis we showed that a single infusion
of FCM in non-dialysis CKD patients causes significant
and prolonged reduction in serum phosphate levels and a
decrease in C-terminal FGF23 levels, but no changes in
serum calcium, PTH or 1,25-vit D levels.
FCM and hypophosphatemia
Transient mild-moderate asymptomatic hypophosphatemia
is common among patients receiving FCM, especially in
patients with postpartum iron deficiency anaemia or
uterine bleeding [12,13]. Hypophosphatemia has also
been documented with other available IV iron preparations
such as iron saccharide complexes [15] or iron polymaltose
[16], but not with low molecular weight iron dextran [7] or
iron isomaltoside [18]. The mechanisms of the decrease in
serum phosphate are unknown, and the differences in the
hypophosphatemic effect observed with various IV iron
preparations remain unclear.
Several mechanisms have been suggested to explain the
hypophosphatemia induced by IV iron therapy, including
Table 4 Baseline characteristics of hypophosphatemic and non-hypophosphatemic patients
Hypophosphatemic Non-hypophosphatemic
p-value
(n = 35) (n = 12)
Age(years) 72.3(11.2) 72.5(13.5) ns
Serum creatinine, mg/dL 2.5(1) 2.7(0.7) ns
eGFR, ml/min/1.73 m2 26.6(10.4) 24.6(10.4) ns
Haemoglobin, g/dL 10(0.6) 10(0.8) ns
Ferritin, ng/mL 64.1(58.3) 78.5(72.2) ns
Transferrin saturation, % 14.6(6.4) 14.6(6.7) ns
FCM, dosage(mg) 966.4(77.9) 987(31.6) ns
Use of phosphate binders, n(%) 3(8.5) 1(8.3) ns
Use of active vitamin D, n(%) 14(40) 4(33.3) ns
Calcium, mg/dL 9.3(0.4) 9.3(0.6) ns
Phosphate, mg/dL 4.1(0.8) 4.5(0.7) ns
PTH, pg/mL 147.8(31.6-600) 84(2.5-404.9) ns
25-hydroxyvitamin D, ng/mL 12.5(6) 13.8(8.5) ns
1,25 dihydroxyvitamin D, pg/mL 10.3(4) 8.55(2) ns
Fibroblast growth factor 23, RU/mL 437.5(44.9-2415) 844.1(148.4-4079.2) ns
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cellular uptake of extracellular phosphate [13], phosphate
binding to FCM via electrostatic interaction [29], and
renal phosphate wasting due to the direct toxic effect of
iron on renal tubular cells [22,23]. Finally, it has been
suggested that FGF23, by reducing renal phosphate
reabsorption and inhibiting 1α-hydroxylation of vitamin D,
may play an etiologic role in the development of iron-
related hypophosphatemia [15,16]. In our study, the per-
sistence of hypophosphatemia over 12 weeks despite the
discontinuation of FCM argues against the extracellular
uptake of phosphate or phosphate binding to FCM, as
mechanisms of hypophosphatemia. We did not measure
the fractional tubular reabsorption of phosphate, which
may have allowed us to confirm the effect of FCM on renal
phosphate transport.
It has been proposed that IV iron leads to
hypophosphatemia by direct proximal tubular damage,
resulting in a specific decrease in tubular phosphate
reabsorption, but without other manifestations of a
generalized proximal tubular toxicity, such as glucosuria
or aminoaciduria [16]. The discontinuation of iron usually
results in the rapid normalization of this disorder [25],
suggesting that other mechanisms, rather than direct
renal tubular damage, may be involved in the onset of
hypophosphatemia. Furthemore, the high molecular mass
of some IV iron preparations such as iron polymaltose
(462,000 daltons) or FCM (150,000 daltons) may make
their excretion through urine difficult, arguing against the
direct toxic effect of iron on renal tubular cells [30].
However, it is possible that tubular damage inducedby iron therapy is more likely in subjects with pre-existing
CKD and anaemia treated with high doses of iron prepara-
tions. In fact iron accumulates in proximal tubular lyso-
somes in patients with proteinuria and/or chronic renal
failure [31]. In rats subjected to a partial nephrectomy,
the accumulation of iron in the cells of the proximal
tubule was found to correlate with proteinuria, tubule
damage and impairment of glomerular filtration [32].
Recently Tolouian et al. reported extensive deposits of
iron in the mesangium and in the interstitial histiocytes in
a patient with advanced diabetic nephropathy treated with
ferumoxytol, another high molecular weight iron prepar-
ation, whereas renal iron deposition was not observed in
another patient receiving IV iron dextran [33]. It seems
that the intrinsic cytotoxic potential of IV iron may be
dependend on the nature of the carbohydrate polymers
employed, which appear to determine cellular iron uptake
and the capacity of these compounds to induce cellular
damage [34].
FCM and FGF23
In our study, FCM induces a decrease in FGF23 levels.
This finding differs from previous studies which de-
scribed an increased in intact FGF23 concentrations
after IV iron therapy in patients with iron deficiency
anaemia, normal renal function and normal baseline
FGF23 levels [15,16,30]. In haemodialysis patients, IV
saccharated ferric oxide or low molecular weight iron
dextran resulted in an elevation in intact FGF23 levels
accompanied by a reduction in PTH levels, but without
changes in phosphate levels [24,25]. However, in a recent
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was found between iron administration and serum intact
FGF23 levels [35].
Our data suggest that in the CKD population, FCM
has a negative effects on C-terminal FGF23 levels. Since
FGF23 levels are highly regulated by serum phosphate
or metabolic changes associated with hypophosphatemia
[36], we can postulate that the resulting fall in phosphate
levels as a consequence of iron-tubular toxicity would be
expected to suppress FGF23 levels. However, in our
study we did not find a relationship between the decline
in phosphate and FGF23 levels, and changes in FGF23
levels did not differ between hypophosphatemic and
non-hypophosphatemic patients, suggesting that the
decrease in FGF23 was not related to the reduction
in serum phosphate.
An unexpected finding in our study was the fact
that FCM had no effect on 1,25-vit D or PTH levels.
In subjects with normal renal function, FCM induces
increased urinary fractional excretion of phosphate,
decreased 1,25- vit D levels and increased PTH levels
[37]. On the other hand, in hemodialysis patients,
some iron preparations induce a reduction in PTH
levels and no changes in 1,25- vit D levels [24,25]. It
may be speculated that in CKD patients, the effect of
intact FGF23 to suppress renal production of 1,25 vit D
may be less pronounced, and the direct effect of FGF23 to
suppress PTH secretion might be augmented.
Lower serum iron concentrations are associated with
elevated FGF23 levels measured with a C-terminal FGF23
but not with an intact FGF23 assay [38,39]. It has been
suggested that iron deficiency may result in an increased
rate of proteolytic cleavage of the intact and biologically
active hormone to inactive C- and N- terminal fragments
[40,41], although a recent western blotting analysis did
not confirm this hypothesis [42].
In a population with iron deficiency, improvement in
iron status with iron sulphate was associated with a
decrease in plasma C-terminal FGF23 levels [43]. Thus,
we suggest that FCM may have a negative effect on the
production and/or secretion of FGF23 by bone cells.
Iron overload is associated with osteoporosis, with a
decrease in bone formation without changes in bone
resorption [44]. Iron could slow down bone formation
by inhibiting osteoblast progenitor cell differentiation
[45]. FGF23 is expressed in osteoblast/osteocyte lineage
cells [38], and osteoblastic bone formation is a potent
modulator of FGF23 production and release into the
bloodstream [46]. Therefore, we can postulate that if
iron therapy has a negative effect on bone formation, it
may also have a blunting effect on C-terminal FGF23
synthesis and secretion from osteoblasts. Finally, some
iron preparations, such as FCM, may simultaneously
inhibit FGF23 degradation in osteocytes, leading to anincrease in intact FGF23 and reduced serum phosphate
levels [37].FCM and vitamin D treatment
In our study we also explored the influence of active
vitamin D treatment on changes in FGF23 levels during
FCM infusion. In the group of untreated vitamin D
patients, FGF23 levels decreased, while this response
was mitigated in the group of patients given vitamin D.
These results are in keeping with the observation that
vitamin D stimulates FGF23 production in osteoblasts
[47], and also increases serum FGF23 levels in haemodi-
alysis patients [48]. Therefore, we suggest that treatment
with active vitamin D may play a role for maintaining
elevated levels of FGF23 in non-dialysis CKD patients
receiving FCM.Limitations of the study
The strengths of this study include the use of a prospect-
ive sample of non-dialysis CKD patients treated with
FCM with a long follow-up period, and uniform bone
mineral metabolism data acquisition. There are, how-
ever, several potential limitations that deserve mention.
Firstly, this was a secondary analysis of an open-label
single-arm clinical trial that lacked a concurrent control
group. These limitations prevented definitive conclu-
sions to be drawn about the effect of FCM on serum
phosphate in CKD patients. Secondly, we did not
measure the fractional tubular reabsorption of phos-
phate and bone turnover markers were not available
in our cohort. Thus, the direct effect of FCM on
renal phosphate transport and bone metabolism and
FGF23 synthesis could not be assessed. Thirdly, we
did not determine the biologically active intact FGF23.
This is important because of the known divergence of
intact FGF23 and C-terminal FGF23 levels in the setting
being studied, namely iron deficiency. Finally, the small
sample size limited the ability of the study to analyse
all of the factors that may have influenced the changes in
phosphate levels.Conclusions
Treatment with FCM for non-dialysis CKD patients with
iron-deficiency anaemia induces reduction in serum
phosphate levels that persists for three months. FCM
causes a significant decrease in FGF23 levels without
changes in other bone metabolism parameters. Further
studies are needed to fully bring to light the mechanisms
by which FCM modulates phosphate levels and disrupts
FGF23 metabolism in CKD patients, and to determine
whether long-term administration of FCM may induce
hypophosphatemic osteomalacia in this population.
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